Common use of Commercial Development Plan Clause in Contracts

Commercial Development Plan. The Licensee will develop, manufacture and market the immunotherapy product PANVAC® and other Vaccine candidates such as Brachyury containing vaccine for therapy of colorectal cancer. Steps followed by Licensee to develop and commercialize PANVAC and other Vaccine candidates such as Brachyury containing vaccine are summarized below: [***] · XXX license reference number (L-XXX-200X/0) · Reporting period · Catalog number and units sold of each Licensed Product (domestic and foreign) · Gross Sales per catalog number per country · Total Gross Sales · Itemized deductions from Gross Sales · Total Net Sales · Earned Royalty Rate and associated calculations · Gross Earned Royalty · Adjustments for Minimum Annual Royalty (MAR) and other creditable payments made · Net Earned Royalty due 1 A US 250 62,500 1 A UK 32 16,500 1 A France 25 15,625 2 B US 0 0 3 C US 57 57,125 4 D US 12 1,500 Total Gross Sales 153,250 Less Deductions: Freight 3,000 Returns 7,000 Total Net Sales 143,250 Royalty Rate 8 % Royalty Due 11,460 Less Creditable Payments 10,000

Appears in 2 contracts

Samples: Patent License Agreement (Bavarian Nordic a/S / ADR), Patent License Agreement (Bavarian Nordic a/S / ADR)

AutoNDA by SimpleDocs

Commercial Development Plan. The Licensee will develop, manufacture and market the immunotherapy product PANVAC® and other Vaccine candidates such as Brachyury containing vaccine for therapy of colorectal cancerbreast, non-small cell lung and other cancers within the Licensed Field of Use. Steps followed by Licensee to develop and commercialize PANVAC and other Vaccine candidates such as Brachyury containing vaccine are summarized below: [***] · XXX license reference number (L-XXX-200X/0) · Reporting period · Catalog number and units sold of each Licensed Product (domestic and foreign) · Gross Sales per catalog number per country · Total Gross Sales · Itemized deductions from Gross Sales · Total Net Sales · Earned Royalty Rate and associated calculations · Gross Earned Royalty · Adjustments for Minimum Annual Royalty (MAR) and other creditable payments made · Net Earned Royalty due 1 A US 250 62,500 1 A UK 32 16,500 1 A France 25 15,625 2 B US 0 0 3 C US 57 57,125 4 D US 12 1,500 Total Gross Sales 153,250 Less Deductions: Freight 3,000 Returns 7,000 Total Net Sales 143,250 Royalty Rate 8 % Royalty Due 11,460 Less Creditable Payments 10,000

Appears in 2 contracts

Samples: Patent License Agreement (Bavarian Nordic a/S / ADR), Patent License Agreement (Bavarian Nordic a/S / ADR)

AutoNDA by SimpleDocs
Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!